SynthesisFrontiers in microbiology2024
Prevalence of colistin resistance in clinical isolates of
Synthesis in Frontiers in microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Prevalence of colistin resistance in clinicalFuture microbiology · 2025Pooled it
- Global prevalence and antibiotic resistance profiles of carbapenem-resistantFrontiers in microbiology · 2025Pooled it
- Article
- WGS reveals high-risk clones of Pseudomonas aeruginosa harbouring extensive antimicrobial and predicted anti-phage defense systems recovered from diabetic foot ulcer patients in Egypt.BMC microbiology · 2026Article
- Bacteriological Profile and Antibiotic Sensitivity Pattern of Burn Wounds in a Tertiary Burn Care Center.Cureus · 2026Article
- Colistin-resistance amongJAC-antimicrobial resistance · 2026Review
- Molecular characteristics of chromosome-mediated colistin resistance in carbapenem-resistant Pseudomonas aeruginosa isolates from a tertiary hospital in China.BMC microbiology · 2026Article
- Colistin Resistance: From Laboratory Research to Modern Clinical Management.Antibiotics (Basel, Switzerland) · 2026Review
- Magnesium depletion by Candida albicans unleashes two unusual modes of colistin resistance in Pseudomonas aeruginosa with different fitness costs.PLoS biology · 2026Article
- Molecular Mechanisms Underlying the Pathogenicity ofMedicina (Kaunas, Lithuania) · 2026Review
- Synergistic effects of meropenem, amikacin, and ciprofloxacin against carbapenem resistant Pseudomonas aeruginosa isolates.Scientific reports · 2026Article
- Clinical Distribution and Antimicrobial Resistance Characteristics ofInfection and drug resistance · 2026Article
- Article
- Colistin resistance in the era of antimicrobial resistance: challenges and strategic countermeasures.Folia microbiologica · 2025Review
- In Vitro Antimicrobial Activity of the Novel Antimicrobial Peptide OMN51 Against Multi-Drug-ResistantJournal of clinical medicine · 2025Article
- The Genetic Background and Culture Medium Only Marginally Affect the In Vitro Evolution ofAntibiotics (Basel, Switzerland) · 2025Article
- Efficacy of Endolysin LysAB1245 Combined with Colistin as Adjunctive Therapy Against Colistin-Resistant Gram-Negative Bacteria.Antibiotics (Basel, Switzerland) · 2025Article
- Penfluridol synergizes with colistin to reverse colistin resistance in Gram-negative bacilli.Scientific reports · 2025Article
- Colistin Treatment Outcomes in Gram-Negative Bacterial Infections in the Northeast of Romania: A Decade of Change Through Pandemic Challenges.Antibiotics (Basel, Switzerland) · 2025Article
- A Comprehensive Overview of Antibacterial Agents for Combating Multidrug-Resistant Bacteria: The Current Landscape, Development, Future Opportunities, and Challenges.Antibiotics (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The emergence of resistance to colistin, the last resort for treating severe infections caused by Method: A comprehensive search of MEDLINE (PubMed), Web of Science, and Scopus databases was conducted to identify relevant articles published until December 2023. Subsequently, a meta-analysis was performed using Stata software to examine the pooled prevalence of colistin resistance and to conduct subgroup analyses. Results: A total of 619 studies were included in the meta-analysis, revealing a global prevalence of colistin resistance of 1% among all Conclusion: The increase in colistin resistance in
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.